Digi unit meets expected CDC monitoring guidelines for Covid-19 vaccines

Temperature monitoring will protect vaccines from development through distribution


The SmartSense division of Digi International announced this week that its monitoring services meet expected guidelines from the U.S. Centers for Disease Control and Prevention (CDC) for handling Covid-19 vaccines and that its solutions will support the entire vaccine cold chain from manufacturers to end-point providers.

At present, SmartSense technologies collect more than 10 million sensor readings per day in 28,000 retail pharmacy locations and their supporting distribution centers.

The CDC is expected to mandate continuous temperature monitoring for pharmacies to receive and distribute forthcoming Covid-19 vaccines. To meet the requirement, SmartSense provides automated wireless-monitoring and task-management tools that ensure the product remains at the proper temperature and that workers handle the inventory correctly.

With many vaccine candidates requiring frozen transportation and storage, the division reports that it can support such conditions without upgrades or hardware changes, and that its sensors can monitor the ultra-cold conditions required for vaccine delivery.

“Our pharmacy customers have already entrusted us to protect more than $2 billion in refrigerated inventory,” said Kevin C. Riley, president of SmartSense. “In addition, we’re also working with hospitals, clinics and transportation companies that use our technology for similar applications.

Digi International is a global provider of business and mission-critical Internet of Things (IoT) connectivity products and resources. Boston-based SmartSense, Digi’s IOT Solutions division, serves more than 2,000 organizations in 75 countries, including at Walmart, CVS Health, SpaceX, Apple, Coca Cola, McDonald’s and the US Department of State, according to the company website.